According to Merck's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.55913. At the end of 2023 the company had a P/S ratio of 4.60.
Year | P/S ratio | Change |
---|---|---|
2023 | 4.60 | -3.15% |
2022 | 4.75 | 19.38% |
2021 | 3.97 | -13.85% |
2020 | 4.61 | -6.41% |
2019 | 4.93 | 5.25% |
2018 | 4.68 | 22.58% |
2017 | 3.82 | -6.29% |
2016 | 4.08 | 9.63% |
2015 | 3.72 | -2.54% |
2014 | 3.82 | 14.68% |
2013 | 3.33 | 26.93% |
2012 | 2.62 | 9.62% |
2011 | 2.39 | -0.99% |
2010 | 2.42 | -41.67% |
2009 | 4.14 | 53.66% |
2008 | 2.69 | -48.35% |
2007 | 5.22 | 24.95% |
2006 | 4.18 | 32.42% |
2005 | 3.15 | 1.89% |
2004 | 3.09 | -32.21% |
2003 | 4.56 | 58.76% |
2002 | 2.88 | 1.15% |
2001 | 2.84 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 4.10 | -26.28% | ๐บ๐ธ USA |
Novartis NVS | 3.88 | -30.28% | ๐จ๐ญ Switzerland |
Pfizer PFE | 2.69 | -51.68% | ๐บ๐ธ USA |
Abbott Laboratories ABT | 4.92 | -11.55% | ๐บ๐ธ USA |
Eli Lilly LLY | 21.7 | 289.91% | ๐บ๐ธ USA |
Amgen AMGN | 5.41 | -2.77% | ๐บ๐ธ USA |
Sanofi SNY | 2.41 | -56.66% | ๐ซ๐ท France |
Bristol-Myers Squibb BMY | 2.44 | -56.17% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 2.32 | -58.34% | ๐ฌ๐ง UK |
Teva Pharmaceutical Industries TEVA | 0.9982 | -82.04% | ๐ฎ๐ฑ Israel |